Challenge to Develop Intranasal Immunotherapy for Brain Tumors
Professor Anstevan's Research Team at Seoul St. Mary's Hospital
Selected for Ministry of Science and ICT’s Young Researchers Project
Seoul St. Mary's Hospital announced on February 2 that the research team led by Professor Anstevan in the Department of Neurosurgery will begin research on an immunotherapy for glioblastoma based on intranasal administration, which delivers immune cells to the brain via the nasal passage.
The study has been selected as a project under the Ministry of Science and ICT's Basic Research Program, "Young Researchers - Pioneering Research." The research period is three years, with a total funding of 300 million won.
Anstevan, Professor of Neurosurgery at Seoul St. Mary's Hospital. Seoul St. Mary's Hospital
View original imageGlioblastoma is the most common malignant primary brain tumor in adults. In Korea, approximately 600 to 800 new cases are diagnosed each year. Even after maximal tumor resection followed by concurrent chemotherapy and radiation therapy, the average survival period remains less than two years. The five-year survival rate is below 10%. The standard chemotherapy drug, temozolomide, extends average survival by only about two months. No new drug has yet demonstrated clinically meaningful survival benefits.
While immuno-oncology therapies have shown efficacy in several cancer types, glioblastoma is considered an exception. Due to its low mutational burden and strongly immunosuppressive tumor microenvironment, it is widely believed that immune checkpoint inhibitors alone are unlikely to be effective.
Adoptive immune cell therapy is gaining attention as an alternative to overcome these limitations. This approach involves infusing externally enhanced immune cells to directly attack the tumor. Some potential has been observed in preclinical and early clinical studies. However, intravenous administration faces structural limitations, as the blood-brain barrier hinders efficient delivery to the brain and increases the risk of systemic side effects.
Professor Anstevan's team has focused on intranasal administration as a way to bypass the blood-brain barrier. This non-invasive approach delivers immune cells directly to the brain through the nasal mucosa. It allows for repeated dosing and is considered advantageous for reducing systemic side effects. In previous preclinical studies, the team confirmed that when immune cells such as chimeric antigen receptor T (CAR-T) cells were administered intranasally, they reached the brain tumor site and demonstrated antitumor effects.
This project will focus on elucidating the mechanisms by which intranasally administered immune cells reach the brain and tumor sites. The team also plans to verify cell engineering strategies to improve delivery efficiency and combination therapy strategies to modulate immunosuppressive factors in the tumor microenvironment.
The research team has already secured basic preclinical data on brain delivery and antitumor efficacy. Based on this, they are conducting follow-up preclinical studies, including tracking delivery routes and analyzing changes in the tumor microenvironment.
If intranasal immune cell delivery technology is established, it is expected to evolve into a platform technology that can be expanded not only to glioblastoma but also to other central nervous system diseases, such as brain metastases.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Professor Anstevan said, "We aim to verify a new possibility for glioblastoma treatment through intranasal immune cell therapy, which overcomes the limitations of systemic administration and direct intratumoral injection," adding, "We hope to establish delivery mechanisms and optimization strategies to develop this into a practical therapeutic alternative."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.